Pharming to part-divest subsidiary to save cash for Rhucin
This article was originally published in Scrip
Executive Summary
The Dutch biotech company Pharming is to reduce its costs by part-divesting its wholly owned subsidiary DNage to fully focus on the commercialisation of its lead product Rhucin (recombinant human C1 inhibitor).